Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

VM26 in malignant hematological diseases. A phase II study

U Tirelli, A Carbone, G Franchin

    Cancer Chemotherapy and Pharmacology
    |January 1, 1982
    PubMed
    Summary

    This Phase II study evaluated VM26 in malignant hematological diseases. VM26 showed activity in Non-Hodgkin

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease.

    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2000
    Same author

    Association between elevated prolactin levels and circulating erythroid precursors in dialyzed patients.

    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·2000
    Same author

    Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma.

    Leukemia·2000
    Same author

    The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma.

    Leukemia·2000
    Same author

    Can Reed-Sternberg cells of classic Hodgkin's disease be considered B-cells?

    Advances in clinical pathology : the official journal of Adriatic Society of Pathology·2000
    Same author

    Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma.

    Cancer·2000

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Pharmacology

    Background:

    • Malignant hematological diseases encompass a range of cancers affecting blood, bone marrow, and lymph nodes.
    • Phase II studies are crucial for assessing the efficacy and safety of novel therapeutic agents in specific patient populations.

    Purpose of the Study:

    • To evaluate the efficacy and toxicity of VM26 in patients with malignant hematological diseases.
    • To determine response rates and safety profiles in various hematologic malignancies.

    Main Methods:

    • A Phase II clinical trial involving 33 consecutive patients with malignant hematological diseases.
    • Patients included those with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Myeloma, Hodgkin's Disease (HD), Acute Lymphoblastic Leukemia (ALL), and Polycythemia Vera.

    Related Experiment Videos

  • Treatment involved VM26, with response and toxicity assessments.

    • Main Results:

    • Two complete responses (CR) were observed in NHL patients (5+ and 20+ weeks).
    • Five partial responses (PR) were noted across NHL, CLL, Myeloma, and HD patients.
    • Hematologic toxicity was the primary concern, affecting ten patients, with one experiencing severe myelosuppression. Severe asthenia linked to VM26 occurred in three patients.

    Conclusions:

    • VM26 demonstrated activity in malignant hematological diseases, particularly in NHL.
    • The toxicity profile, mainly hematologic and asthenia, requires careful management.
    • Further investigation may be warranted for specific hematologic malignancies.